Search

Your search keyword '"Cabibbo, A"' showing total 3,551 results
Start Over Author "Cabibbo, A"
3,551 results on '"Cabibbo, A"'

203. Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

Author

Celsa, Ciro, primary, Cabibbo, Giuseppe, additional, Di Maria, Gabriele, additional, Vaccaro, Marco, additional, Battaglia, Salvatore, additional, Maria Rizzo, Giacomo Emanuele, additional, Ciccia, Roberta, additional, Grova, Alessandro, additional, Salvato, Mauro, additional, Giuffrida, Paolo, additional, Giacchetto, Marco, additional, Rancatore, Gabriele, additional, Grassini, Maria Vittoria, additional, Antonucci, Michela, additional, Morana, Piera, additional, Enea, Marco, additional, and Camma, Calogero, additional

Published
2023
Full Text
View/download PDF

204. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Author

Persano, Mara, primary, Rimini, Margherita, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shigeo, Shimose, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Presa, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Piscaglia, Fabio, additional, Iavarone, Massimo, additional, Di Costanzo, Giuseppe, additional, Marra, Fabio, additional, Cabibbo, Giuseppe, additional, Foschi, Francesco, additional, Siletta, Marianna, additional, Cascinu, Stefano, additional, Scartozzi, Mario, additional, and Gardini, Andrea Casadei, additional

Published
2023
Full Text
View/download PDF

209. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

Author

Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, Cillo, Umberto, Miele, Luca, HCC Special Interest Group of the Italian Association for the Study of the, Liver, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Miele, Luca (ORCID:0000-0003-3464-0068), HCC Special Interest Group of the Italian Association for the Study of the Liver, Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, Cillo, Umberto, Miele, Luca, HCC Special Interest Group of the Italian Association for the Study of the, Liver, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Miele, Luca (ORCID:0000-0003-3464-0068), and HCC Special Interest Group of the Italian Association for the Study of the Liver

Abstract

Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma have increased the complexity of patient management. A dynamic adaptation of the available staging-based algorithms is required to allow flexible therapeutic allocation. In particular, real-world hepatocellular carcinoma management increasingly relies on factors independent of oncological staging, including patients' frailty, comorbid burden, critical tumour location, multiple liver functional parameters, and specific technical contraindications impacting the delivery of treatment and resource availability. In this Policy Review we critically appraise how treatment allocation strictly based on pretreatment staging features has shifted towards a more personalised treatment approach, in which expert tumour boards assume a central role. We propose an evidence-based framework for hepatocellular carcinoma treatment based on the novel concept of multiparametric therapeutic hierarchy, in which different therapeutic options are ordered according to their survival benefit (ie, from surgery to systemic therapy). Moreover, we introduce the concept of converse therapeutic hierarchy, in which therapies are ordered according to their conversion abilities or adjuvant abilities (ie, from systemic therapy to surgery).

Published
2023

210. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Author

Lai, Quirino, De Matthaeis, Nicoletta, Finotti, Michele, Galati, Giovanni, Marrone, Giuseppe, Melandro, Fabio, Morisco, Filomena, Nicolini, Daniele, Pravisani, Riccardo, Giannini, Edoardo G, Aglitti, A, Aliberti, C, Baccarani, U, Bhoori, S, Borzio, M, Brancaccio, G, Burra, P, Cabibbo, G, Casadei Gardini, A, Carrai, P, Cillo, U, Conti, F, Cucchetti, A, D'Ambrosio, R, Dell'Unto, C, Di Costanzi, Gg, Di Sandro, S, Foschi, Fg, Fucilli, F, Gambato, M, Gasbarrini, Antonio, Giuliante, Felice, Ghinolfi, D, Grieco, Antonio, Gruttaduria, S, Guarino, M, Kostandini, A, Iavarone, M, Lenci, I, Levi Sandri, Gb, Losito, F, Lupo, Lg, Manzia, Tm, Mazzocato, S, Mescoli, C, Miele, Luca, Muley, M, Persico, M, Plaz Torres, Mc, Pompili, Maurizio, Ponziani, Francesca Romana, Rapaccini, Gian Ludovico, Rendina, M, Renzulli, M, Rossi, Marco, Rreka, E, Russo, Fp, Sacco, R, Sangiovanni, A, Sessa, A, Simonetti, N, Sposito, C, Tortora, R, Trevisani, F, Viganò, L, Viganò, M, Villa, E, Vincenzi, V, Violi, P, Vitale, A, Gasbarrini, A (ORCID:0000-0002-7278-4823), Giuliante, F (ORCID:0000-0001-9517-8220), Grieco, A (ORCID:0000-0002-0544-8993), Miele, L (ORCID:0000-0003-3464-0068), Pompili, M (ORCID:0000-0001-6699-7980), Ponziani, FR (ORCID:0000-0002-5924-6238), Rapaccini, GL (ORCID:0000-0002-6467-857X), Rossi, M (ORCID:0000-0002-4539-5670), Lai, Quirino, De Matthaeis, Nicoletta, Finotti, Michele, Galati, Giovanni, Marrone, Giuseppe, Melandro, Fabio, Morisco, Filomena, Nicolini, Daniele, Pravisani, Riccardo, Giannini, Edoardo G, Aglitti, A, Aliberti, C, Baccarani, U, Bhoori, S, Borzio, M, Brancaccio, G, Burra, P, Cabibbo, G, Casadei Gardini, A, Carrai, P, Cillo, U, Conti, F, Cucchetti, A, D'Ambrosio, R, Dell'Unto, C, Di Costanzi, Gg, Di Sandro, S, Foschi, Fg, Fucilli, F, Gambato, M, Gasbarrini, Antonio, Giuliante, Felice, Ghinolfi, D, Grieco, Antonio, Gruttaduria, S, Guarino, M, Kostandini, A, Iavarone, M, Lenci, I, Levi Sandri, Gb, Losito, F, Lupo, Lg, Manzia, Tm, Mazzocato, S, Mescoli, C, Miele, Luca, Muley, M, Persico, M, Plaz Torres, Mc, Pompili, Maurizio, Ponziani, Francesca Romana, Rapaccini, Gian Ludovico, Rendina, M, Renzulli, M, Rossi, Marco, Rreka, E, Russo, Fp, Sacco, R, Sangiovanni, A, Sessa, A, Simonetti, N, Sposito, C, Tortora, R, Trevisani, F, Viganò, L, Viganò, M, Villa, E, Vincenzi, V, Violi, P, Vitale, A, Gasbarrini, A (ORCID:0000-0002-7278-4823), Giuliante, F (ORCID:0000-0001-9517-8220), Grieco, A (ORCID:0000-0002-0544-8993), Miele, L (ORCID:0000-0003-3464-0068), Pompili, M (ORCID:0000-0001-6699-7980), Ponziani, FR (ORCID:0000-0002-5924-6238), Rapaccini, GL (ORCID:0000-0002-6467-857X), and Rossi, M (ORCID:0000-0002-4539-5670)

Abstract

Aim To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51-0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35-0.83; p = 0.006). Conclusions Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.

Published
2023

211. Precision tests of the Standard Model with Kaon decays at CERN

Author

Ambrosino, F., Antonelli, A., Anzivino, G., Arcidiacono, R., Baldini, W., Balev, S., Batley, J.R., Behler, M., Bifani, S., Biino, C., Bizzeti, A., Bloch-Devaux, B., Bocquet, G., Bolotov, V., Bucci, F., Cabibbo, N., Calvetti, M., Cartiglia, N., Ceccucci, A., Cenci, P., Cerri, C., Cheshkov, C., Chèze, J.B., Clemencic, M., Collazuol, G., Costantini, F., Cotta Ramusino, A., Coward, D., Cundy, D., Dabrowski, A., D'Agostini, G., Dalpiaz, P., Damiani, C., Danielsson, H., De Beer, M., Dellacasa, G., Derré, J., Dibon, H., Di Filippo, D., DiLella, L., Doble, N., Duk, V., Engelfried, J., Eppard, K., Falaleev, V., Fantechi, R., Fidecaro, M., Fiorini, L., Fiorini, M., Fonseca Martin, T., Frabetti, P.L., Fucci, A., Gallorini, S., Gatignon, L., Gersabeck, E., Gianoli, A., Giudici, S., Gonidec, A., Goudzovski, E., Goy Lopez, S., Gushchin, E., Hallgren, B., Hita-Hochgesand, M., Holder, M., Hristov, P., Iacopini, E., Imbergamo, E., Jeitler, M., Kalmus, G., Kekelidze, V., Kleinknecht, K., Kozhuharov, V., Kubischta, W., Kurshetsov, V., Lamanna, G., Lazzeroni, C., Lenti, M., Leonardi, E., Litov, L., Madigozhin, D., Maier, A., Mannelli, I., Marchetto, F., Marel, G., Markytan, M., Marouelli, P., Martini, M., Masetti, L., Massarotti, P., Mazzucato, E., Michetti, A., Mikulec, I., Misheva, M., Molokanova, N., Monnier, E., Moosbrugger, U., Morales Morales, C., Moulson, M., Movchan, S., Munday, D.J., Napolitano, M., Nappi, A., Neuhofer, G., Norton, A., Numao, T., Obraztsov, V., Palladino, V., Patel, M., Pepe, M., Peters, A., Petrucci, F., Petrucci, M.C., Peyaud, B., Piandani, R., Piccini, M., Pierazzini, G., Polenkevich, I., Popov, I., Potrebenikov, Yu., Raggi, M., Renk, B., Retière, F., Riedler, P., Romano, A., Rubin, P., Ruggiero, G., Salamon, A., Saracino, G., Savrié, M., Scarpa, M., Semenov, V., Sergi, A., Serra, M., Shieh, M., Shkarovskiy, S., Slater, M.W., Sozzi, M., Spadaro, T., Stoynev, S., Swallow, E., Szleper, M., Valdata-Nappi, M., Valente, P., Vallage, B., Velasco, M., Veltri, M., Venditti, S., Wache, M., Wahl, H., Walker, A., Wanke, R., Widhalm, L., Winhart, A., Winston, R., Wood, M.D., Wotton, S.A., Yushchenko, O., Zinchenko, A., and Ziolkowski, M.

Published
2016
Full Text
View/download PDF

213. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini, and Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini

Subjects
Cancer Research, Settore MED/12 - Gastroenterologia, Lenvatinib, Oncology, Advanced HCC, Atezolizumab plus bevacizumab, First-line therapy, General Medicine
Abstract

Purpose: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. Methods: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea). Results: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab. Objective response rate (ORR) was 38.6% for patients receiving lenvatinib, and 27.3% for patients receiving atezolizumab plus bevacizumab (p < 0.01; odds ratio 0.60). For patients who achieved complete response (CR), overall survival (OS) was not reached in both arms, but the result from univariate Cox regression model showed 62% reduction of death risk for patients treated with atezolizumab plus bevacizumab (p = 0.05). In all multivariate analyses, treatment arm was not found to be an independent factor conditioning OS. Comparing ORR achieved in the two arms, there was a statistically significant difference in favor of lenvatinib compared to atezolizumab plus bevacizumab in all subgroups except for Eastern patients, Child-Pugh B patients, presence of portal vein thrombosis, α-feto-protein ≥ 400 ng/mL, presence of extrahepatic disease, albumin-bilirubin (ALBI) grade 2, and no previous locoregional procedures. Conclusion: Lenvatinib achieves higher ORR in all patient subgroups. Patients who achieve CR with atezolizumab plus bevacizumab can achieve OS so far never recorded in HCC patients. This study did not highlight any factors that could identify patient subgroups capable of obtaining CR.

Published
2022

214. Inhalable polymeric microparticles as pharmaceutical porous powder for drug administration

Author

Emanuela Fabiola Craparo, Marta Cabibbo, Salvatore Emanuele Drago, Luca Casula, Francesco Lai, Gennara Cavallaro, Craparo, Emanuela Fabiola, Cabibbo, Marta, Emanuele Drago, Salvatore, Casula, Luca, Lai, Francesco, and Cavallaro, Gennara

Subjects
Porous microparticles, Drug Carriers, Polymers, Settore CHIM/09 - Farmaceutico Tecnologico Applicativo, Administration, Inhalation, Pharmaceutical Science, Pulmonary administration, Rapamycin, Powders, Particle Size, Porosity, α,β-Poly(N-2-hydroxyethyl)-Dl-ASPARTAMIDE (PHEA)
Abstract

In this work, the production of inhalable polymeric microparticles with modulable porosity is described. The starting polymeric material was the PHEA-g-RhB-g-PLA graft copolymer, which was suitably processed by spray drying (SD). Thanks to the addition of AB (weight percentage equal to 10 and 20 % with respect to the polymer) in the liquid feed, three biocompatible matrices were obtained with an increasing porosity in terms of pore volume (from 0.015 to 0.024 cc/g) and pore average diameter (from 1.942 to 3.060 nm), a decreasing tapped density values (from 0.75 to 0.50), and favorable aerosolization characteristics. These differences were high-lighted also by a significant increase in the release of Rapamycin from the sample which showed the higher porosity (31.0 wt% after 24 hrs incubation) than the sample with the lowest porosity (14.9 wt%) in simulated lung fluid.

Published
2022

215. Laser Defocusing Effect on the Microstructure and Defects of 17-4PH Parts Additively Manufactured by SLM at a Low Energy Input

Author

Paola Leo, Marcello Cabibbo, Antonio Del Prete, Sara Giganto, Susana Martínez-Pellitero, and Joaquin Barreiro

Subjects
characterization, hardness, iron alloy, laser defocusing, microstructure evolution, selective laser melting, Mining engineering. Metallurgy, TN1-997
Abstract

In this paper, the microstructure, defects, hardness, and tensile strength of the 17-4PH specimens manufactured additively using the selective laser melting (SLM) technique were studied. The analyzed parts (10 mm size cubic specimens and tensile specimens) were manufactured with different defocus parameter values (−1, 0, +1 mm) in order to evaluate this effect with a low power laser (38 W). The study was carried out on three different sections of each cubic specimen, one perpendicular to the laser beam or SLM manufacturing direction (transversal section), and another two parallel to the laser beam direction (longitudinal sections). The specimens microstructures were analyzed with an X-ray diffraction technique, as well as optical, scanning electron, and transmission electron microscopes. Image J software was used to characterize the defects and phase ratio. In addition, hardness and tensile tests were performed according to the corresponding standards. The results show that the amount of austenitic phase and the average grain size varied with defocusing. The percentage of defective area was less than 0.25%. The analyzed defocus distance did not affect the number and average size of the defects. Adjusting the defocusing SLM parameter is important for manufacturing parts with good mechanical properties.

Published
2021
Full Text
View/download PDF

216. Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis

Author

Emanuela Fabiola Craparo, Marta Cabibbo, Alice Conigliaro, Maria Magdalena Barreca, Teresa Musumeci, Gaetano Giammona, and Gennara Cavallaro

Subjects
rapamycin (Rapa), polymeric nanoparticles, macrophage targeting, KOdia-PC, atherosclerosis, Pharmacy and materia medica, RS1-441
Abstract

Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques; however, its use requires site-specific accumulation in the vessels involved in the formation of the plaques to avoid the systemic effects resulting from its indiscriminate biodistribution. In this work, a stable pharmaceutical formulation for Rapa was realized as a dried powder to be dispersed extemporaneously before administration. The latter was constituted by mannitol (Man) as an excipient and a Rapa-loaded polymeric nanoparticle carrier. These nanoparticles were obtained by nanoprecipitation and using as a starting polymeric material a polycaprolactone (PCL)/α,β-poly(N-2-hydroxyethyl)-dl-aspartamide (PHEA) graft copolymer. To obtain nanoparticles targeted to macrophages, an oxidized phospholipid with a high affinity for the CD36 receptor of macrophages, the 1-(palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine (KOdia-PC), was added to the starting organic phase. The chemical–physical and technological characterization of the obtained nanoparticles demonstrated that: both the drug loading (DL%) and the entrapment efficiency (EE%) entrapped drug are high; the entrapped drug is in the amorphous state, protected from degradation and slowly released from the polymeric matrix; and the KOdia-PC is on the nanoparticle surface (KP-Nano). The biological characterization demonstrated that both systems are quickly internalized by macrophages while maintaining the activity of the drug. In vitro studies demonstrated that the effect of KP-Nano Rapa-loaded, in reducing the amount of the Phospo-Ser757-ULK1 protein through the inhibition of the mammalian target of rapamycin (mTOR), is comparable to that of the free drug.

Published
2021
Full Text
View/download PDF

218. Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

Author

Orsi, Giulia, Tovoli, Francesco, Dadduzio, Vincenzo, Vivaldi, Caterina, Brunetti, Oronzo, Ielasi, Luca, Conti, Fabio, Rovesti, Giulia, Gramantieri, Laura, Rizzato, Mario Domenico, Pecora, Irene, Argentiero, Antonella, Teglia, Federica, Lonardi, Sara, Salani, Francesca, Granito, Alessandro, Zagonel, Vittorina, Marisi, Giorgia, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Benevento, Francesca, Cucchetti, Alessandro, Piscaglia, Fabio, Cascinu, Stefano, Scartozzi, Mario, and Casadei-Gardini, Andrea

Published
2020
Full Text
View/download PDF

220. Database Design for NoSQL Systems

Author

Bugiotti, Francesca, Cabibbo, Luca, Atzeni, Paolo, Torlone, Riccardo, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Kobsa, Alfred, Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Yu, Eric, editor, Dobbie, Gillian, editor, Jarke, Matthias, editor, and Purao, Sandeep, editor

Published
2014
Full Text
View/download PDF

221. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

Author

Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, Romagnoli, Veronica, Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, and Romagnoli, Veronica

Subjects
Liver Cancer, Pre-TACE-Predict model, medicine.medical_specialty, business.industry, Trans-arterial chemoembolization, Pharmaceutical Science, hepatocellular carcinoma, medicine.disease, Gastroenterology, Complementary and alternative medicine, Internal medicine, Hepatocellular carcinoma, medicine, Pharmacology (medical), Trans arterial chemoembolization, business
Abstract

Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.

Published
2021
Full Text
View/download PDF

222. High-Temperature Equal-Channel Angular Pressing of a T6-Al-Cu-Li-Mg-Ag-Zr-Sc Alloy

Author

Marcello Cabibbo and Chiara Paoletti

Subjects
ECAP, Al-Cu-Mg-Li-Ag-Zr-Sc alloy, secondary-phase precipitates, tangled dislocations, alloy aging, transmission electron microscopy, Production capacity. Manufacturing capacity, T58.7-58.8
Abstract

Equal-channel angular pressing (ECAP) is known to induce significant grain refinement and formation of tangled dislocations within the grains. These are induced to evolve to form low-angle boundaries (i.e., cell boundaries) and eventually high-angle boundaries (i.e., grain boundaries). On the other hand, the precipitation sequence of age hardening aluminum alloys can be significantly affected by pre-straining and severe plastic deformation. Thus, ECAP is expected to influence the T6 response of aluminum alloys. In this study, a complex Al-Cu-Mg-Li-Ag-Zr-Sc alloy was subjected to ECAP following different straining paths. The alloy was ECAP at 460 K via route A, C, and by forward-backward route A (FB-route A) up to four passes. That is, ECAP was carried out imposing billet rotation between passes (route A), billet rotation by +90° between passes (route C), and billet rotation by +90° and inversion upside down between passes (FB-route A). The alloy was also aged at 460 K for different durations after ECAP. TEM microstructure inspections showed a marked influence of the different shearing deformations induced by ECAP on the alloy aging response. The precipitation kinetics of the different hardening secondary phases were affected by shearing deformation and tangled dislocations. In particular, the T1-Al2CuLi phase was the one that mostly showed a precipitation sequence speed up induced by the tangled dislocations formed during ECAP. The T1 phase was found to grow with aging time according to the Lifshitz-Slyozov-Wagner low-power regime.

Published
2021
Full Text
View/download PDF

223. Effect of Low-Temperature Annealing on Creep Properties of AlSi10Mg Alloy Produced by Additive Manufacturing: Experiments and Modeling

Author

Chiara Paoletti, Emanuela Cerri, Emanuele Ghio, Eleonora Santecchia, Marcello Cabibbo, and Stefano Spigarelli

Subjects
creep, aluminum alloys, additive manufacturing, annealing, modeling, Mining engineering. Metallurgy, TN1-997
Abstract

The effects of postprocessing annealing at 225 °C for 2 h on the creep properties of AlSi10Mg alloy were investigated through constant load experiments carried out at 150 °C, 175 °C and 225 °C. In the range of the experimental conditions here considered, the annealing treatment resulted in an increase in minimum creep rate for a given stress. The reduction in creep strength was higher at the lowest temperature, while the effect progressively vanished as temperature increased and/or applied stress decreased. The minimum creep rate dependence on applied stress was modeled using a physically-based model which took into account the ripening of Si particles at high temperature and which had been previously applied to the as-deposited alloy. The model was successfully validated, since it gave an excellent description of the experimental data.

Published
2021
Full Text
View/download PDF

224. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

Author

Edoardo G. Giannini, Giulia Pieri, Sara Labanca, Maria Corina Plaz Torres, Antonio Gasbarrini, Elisabetta Biasini, Claudia Campani, Nora Cazzagon, Francesco Giuseppe Foschi, Andrea Mega, Alberto Masotto, Giovanni Raimondo, Gian Ludovico Rapaccini, Rodolfo Sacco, Eugenio Caturelli, Maria Guarino, Francesco Tovoli, Gianpaolo Vidili, Maurizia Rossana Brunetto, Gerardo Nardone, Gianluca Svegliati-Baroni, Donatella Magalotti, Francesco Azzaroli, Giuseppe Cabibbo, Maria Di Marco, Angelo Sangiovanni, Franco Trevisani, Maurizio Biselli, Paolo Caraceni, Annagiulia Gramenzi, Francesca Benevento, Alessandro Granito, Luca Muratori, Fabio Piscaglia, Federica Bertellini, Fabio Farinati, Giorgio Palano, Filippo Pelizzaro, Barbara Penzo, Elisa Pinto, Gloria Allegrini, Calogero Cammà, Ciro Celsa, Paolo Giuffrida, Caterina Stornello, Mauro Grova, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Valentina Adotti, Stefano Gitto, Fabio Marra, Martina Rosi, Vittoria Bevilacqua, Alberto Borghi, Andrea Casadei Gardini, Fabio Conti, Lucia Napoli, Marco Domenicali, Maria Teresa Migliano, Nicoletta de Matthaeis, Francesca Romana Ponziani, Andrea Olivani, Gabriele Missale, Valentina Cossiga, Mario Capasso, Filomena Morisco, Ester Marina Cela, Antonio Facciorusso, Valentina Lauria, Giorgia Ghittoni, Giorgio Pelecca, Fabrizio Chegai, Fabio Coratella, Mariano Ortenzi, Serena Dell'Isola, Maria Stella Franzè, Carlo Saitta, Assunta Sauchella, Elton Dajti, Federico Ravaioli, Filippo Oliveri, Gabriele Ricco, Veronica Romagnoli, Alessandro Inno, Fabiana Marchetti, Pietro Coccoli, Antonio Malerba, Alberta Cappelli, Rita Golfieri, Cristina Mosconi, Matteo Renzulli, Giannini, Edoardo G, Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria, Sangiovanni, Angelo, Trevisani, Franco, Giannini, E. G., Pieri, G., Labanca, S., Plaz Torres, M. C., Gasbarrini, A., Biasini, E., Campani, C., Cazzagon, N., Foschi, F. G., Mega, A., Masotto, A., Raimondo, G., Rapaccini, G. L., Sacco, R., Caturelli, E., Guarino, M., Tovoli, F., Vidili, G., Brunetto, M. R., Nardone, G., Svegliati-Baroni, G., Magalotti, D., Azzaroli, F., Cabibbo, G., Di Marco, M., Sangiovanni, A., Trevisani, F., Biselli, M., Caraceni, P., Gramenzi, A., Benevento, F., Granito, A., Muratori, L., Piscaglia, F., Bertellini, F., Farinati, F., Palano, G., Pelizzaro, F., Penzo, B., Pinto, E., Allegrini, G., Camma, C., Celsa, C., Giuffrida, P., Stornello, C., Grova, M., Giacchetto, C. M., Rancatore, G., Grassini, M. V., Adotti, V., Gitto, S., Marra, F., Rosi, M., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, F., Napoli, L., Domenicali, M., Migliano, M. T., de Matthaeis, N., Ponziani, F. R., Olivani, A., Missale, G., Cossiga, V., Capasso, M., Morisco, F., Cela, E. M., Facciorusso, A., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Dell'Isola, S., Franze, M. S., Saitta, C., Sauchella, A., Dajti, E., Ravaioli, F., Oliveri, F., Ricco, G., Romagnoli, V., Inno, A., Marchetti, F., Coccoli, P., Malerba, A., Cappelli, A., Golfieri, R., Mosconi, C., and Renzulli, M.

Subjects
Male, Carcinoma, Hepatocellular, Cholestatic liver disease, Outcome, Surveillance, Survival, Treatment, Hepatology, Prognosi, Liver Cirrhosis, Biliary, Risk Factor, Settore MED/12 - GASTROENTEROLOGIA, Liver Neoplasms, Gastroenterology, Prognosis, Risk Factors, Humans, Female, Human, Aged
Abstract

Background: Comprehensive and contemporary data pertaining large populations of patients with Primary Biliary Cholangitis (PBC) and hepatocellular carcinoma (HCC) are missing. Aim: To describe main characteristics and outcome of PBC patients with HCC diagnosed in the new millennium. Methods: Analysing the Italian Liver Cancer registry we identified 80 PBC patients with HCC diagnosed after the year 2000, and described their clinical characteristics, access to treatment and survival. Results: Median age of patients was 71 years and 50.0% were males. Cirrhosis was present in 86.3% of patients, being well-compensated in 58.0%. Median HCC diameter was smaller in patients under surveillance (2.6vs 4.0cm, P=0.007). Curative treatment, feasible in 50.0% of patients, was associated with improved survival compared to palliative and supportive care (42vs 33vs 6 months, P

Published
2022

225. Surveillance for hepatocellular carcinoma with a 3-months interval in 'extremely high-risk' patients does not further improve survival

Author

Filippo Pelizzaro, Giulia Peserico, Marco D'Elia, Nora Cazzagon, Francesco Paolo Russo, Alessandro Vitale, Edoardo G. Giannini, Manuela Piccinnu, Gian Ludovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Andrea Olivani, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Franco Trevisani, Fabio Farinati, Maurizio Biselli, Paolo Caraceni, Francesca Garuti, Annagiulia Gramenzi, Andrea Neri, Valentina Santi, Fabio Piscaglia, Francesco Tovoli, Alessandro Granito, Luca Muratori, Francesca Benevento, Elton Dajti, Giovanni Marasco, Federico Ravaioli, Alberta Cappelli, Rita Golfieri, Cristina Mosconi, Matteo Renzulli, Angela Imondi, Anna Sartori, Barbara Penzo, Elisa Pinto, Ester Marina Cela, Antonio Facciorusso, Valentina Cacciato, Edoardo Casagrande, Alessandro Moscatelli, Gaia Pellegatta, Nicoletta De Matthaeis, Gloria Allegrini, Valentina Lauria, Giorgia Ghittoni, Giorgio Pelecca, Fabrizio Chegai, Fabio Coratella, Mariano Ortenzi, Gabriele Missale, Alessandro Inno, Fabiana Marchetti, Anita Busacca, Calogero Cammà, Vincenzo Di Martino, Giacomo Emanuele Maria Rizzo, Maria Stella Franzè, Carlo Saitta, Assunta Sauchella, Vittoria Bevilacqua, Alberto Borghi, Andrea Casadei Gardini, Fabio Conti, Anna Chiara Dall'aglio, Giorgio Ercolani, Federica Mirici, Claudia Campani, Chiara Di Bonaventura, Stefano Gitto, Pietro Coccoli, Antonio Malerba, Maria Guarino, Maurizia Brunetto, Veronica Romagnoli, Pelizzaro, F., Peserico, G., D'Elia, M., Cazzagon, N., Russo, F. P., Vitale, A., Giannini, E. G., Piccinnu, M., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Farinati, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Santi, V., Piscaglia, F., Tovoli, F., Granito, A., Muratori, L., Benevento, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Imondi, A., Sartori, A., Penzo, B., Pinto, E., Cela, E. M., Facciorusso, A., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., De Matthaeis, N., Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Missale, G., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Casadei Gardini, A., Conti, F., Dall'Aglio, A. C., Ercolani, G., Mirici, F., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Guarino, M., Brunetto, M., Romagnoli, V., Pelizzaro, Filippo, Peserico, Giulia, D'Elia, Marco, Cazzagon, Nora, Russo, Francesco Paolo, Vitale, Alessandro, Giannini, Edoardo G., Piccinnu, Manuela, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Biselli, Maurizio, Caraceni, Paolo, Garuti, Francesca, Gramenzi, Annagiulia, Neri, Andrea, Santi, Valentina, Piscaglia, Fabio, Tovoli, Francesco, Granito, Alessandro, Muratori, Luca, Benevento, Francesca, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Imondi, Angela, Sartori, Anna, Penzo, Barbara, Pinto, Elisa, Cela, Ester Marina, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, Moscatelli, Alessandro, Pellegatta, Gaia, De Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Missale, Gabriele, Inno, Alessandro, Marchetti, Fabiana, Busacca, Anita, Cammà, Calogero, Di Martino, Vincenzo, Rizzo, Giacomo Emanuele Maria, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Bevilacqua, Vittoria, Borghi, Alberto, Casadei Gardini, Andrea, Conti, Fabio, Dall'aglio, Anna Chiara, Ercolani, Giorgio, Mirici, Federica, Campani, Claudia, Di Bonaventura, Chiara, Gitto, Stefano, Coccoli, Pietro, Malerba, Antonio, Guarino, Maria, Brunetto, Maurizia, and Romagnoli, Veronica

Subjects
medicine.medical_specialty, Carcinoma, Hepatocellular, Survival, Hepatocellular carcinoma, Cancer stage, Surveillance interval, Internal medicine, medicine, Humans, Propensity Score, Survival analysis, High risk patients, Hepatology, business.industry, Liver Neoplasms, Settore MED/09 - MEDICINA INTERNA, Gastroenterology, Patient survival, medicine.disease, Survival Analysis, Propensity score matching, Survival Analysi, Liver cancer, business, Median survival, Human
Abstract

Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveillance interval neither reduced the share of patients diagnosed outside the Milano criteria, nor increased their probability to receive curative treatments. The median survival of 6MS patients (55.0 months [45.9–64.0]) was not significantly different from the observed (47.0 months [35.0–58.9]; p = 0.43) and adjusted (44.9 months [33.4–56.4]; p = 0.30) survival of 3MS patients. A propensity score analysis confirmed the absence of a survival advantage for 3MS patients. Conclusions A tightening of surveillance schedule does not increase the diagnosis of early-stage tumors, the feasibility of curative treatments and the survival. Therefore, we should maintain the 6-months interval in the surveillance of viral cirrhotics.

Published
2022

226. Reactive formation of C3N4as a by-product of AISI 1070 parts produced by laser powder bed fusion in N2atmosphere

Author

Gatto, Andrea, Tognoli, Emanuele, Groppo, Riccardo, Cabibbo, Marcello, Gatto, Maria Laura, Sabbatini, Simona, and Mengucci, Paolo

Abstract

In metal additive manufacturing (AM), inert gases are traditionally used to achieve a controlled atmosphere and mitigate the effects of residual reactive gases. However, the interaction between gases and laser processes, particularly in reactive laser powder bed fusion (RL-PBF) technology, offers the possibility of opening up new avenues for material synthesis. In this experimental work, the authors observed the presence of C3N4in the residual powder during the manufacture of AISI 1070 steel parts by L-PBF, indicating a reactive process occurred during parts production. This investigation revealed the formation in the working chamber of a waste product containing C3N4carbon nitride, due to the reaction between the carbon released from the steel and the nitrogen in the chamber. Remarkably, despite carbon depletion, the final product of AISI 1070 steel complies with the specifications of use. Hence, the L-PBF machine was modified to allow black powder sampling from various locations in the chamber. Authors attempted to enhance the production of the C3N4material by increasing the SED up to 7143 J/mm2to sublimate a pure graphite rod and concurrently manufacture parts in AISI 1070, in a nitrogen atmosphere. The results obtained at higher SED values showed that in both cases (graphite rod or AISI 1070 steel) a C3N4compound in the black powder is formed in the investigated atmosphere by reaction of nitrogen atoms with the carbon atoms vaporized by the laser beam. Thus, the study highlights the novel achievement of synthesizing carbon nitride as a high-value by-product while producing functional AISI 1070 steel parts via L-PBF through reaction with nitrogen atmosphere.

Published
2024
Full Text
View/download PDF

230. Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study

Author

Muñoz- Martínez, Sergio, Sapena, Victor, Forner, Alejandro, Bruix, Jordi, Sanduzzi-Zamparelli, Marco, Ríos, José, Bouattour, Mohamed, El Kassas, Mohamed, Guedes Leal, Cassia Regina, Mocan, Tudor, Nault, Jean-Charles, Camargo Pinheiro Alves, Rogerio, Reeves, Helen L., da Fonseca, Leonardo, García-Juárez, Ignacio, Pinato, David J., Varela, María, Alqahtani, Saleh A., Alvares-da-Silva, Mario Reis, Bandi, Juan C., Rimassa, Lorenza, Lozano, Mar, González Santiago, Jesús M., Tacke, Frank, Sala, Margarita, Anders, Maria Margarita, Lachenmayer, Anja, Piñero, Federico, França, Alex, Guarino, María, Elvevi, Alessandra, Cabibbo, Giuseppe, Peck-Radosavljevic, Markus, Rojas, Ángela, Vergara, Mercedes, Braconi, Chiara, Pascual, Sonia, Perelló, Christie, Mello, Vivianne, Rodríguez-Lope, Carlos, Acevedo, Juan, Villani, Rosanna, Hollande, Clemence, Vilgrain, Valérie, Tawheed, Ahmed, Ferguson Theodoro, Carmem, Sparchez, Zeno, Blaise, Lorraine, Viera-Alves, Daniele E., Watson, Robyn, Carrilho, Flair J., Moctezuma-Velázquez, Carlos, D'Alessio, Antonio, Iavarone, Massimo, Reig, María, Ministerio de Sanidad (España), European Association for the Study of the Liver, Cancer Treatment and Research Trust, Wellcome Trust, Cancer Research UK, Instituto de Salud Carlos III, Bristol Myers Squibb Foundation, Muñoz- Martínez, Sergio [0000-0003-0663-0575], Sapena, Victor [0000-0003-4379-6486], Forner, Alejandro [0000-0002-9014-4950], Ríos, José [0000-0002-0716-8784], González Santiago, Jesús M. [0000-0003-4667-4492], Rojas, Ángela [0000-0003-0853-4800], Hollande, Clemence [0000-0002-2287-0635], Muñoz- Martínez, Sergio, Sapena, Victor, Forner, Alejandro, Ríos, José, González Santiago, Jesús M., Rojas, Ángela, Hollande, Clemence, and Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, Jordi Bruix, Marco Sanduzzi-Zamparelli, José Ríos, Mohamed Bouattour, Mohamed El-Kassas, Cassia R. G. Leal, Tudor Mocan, Jean-Charles Nault, Rogerio C. P. Alves, Helen L. Reeves, Leonardo da Fonseca, Ignacio García-Juárez, David J. Pinato, María Varela, Saleh A. Alqahtani, Mario R. Alvares-da-Silva, Juan C. Bandi, Lorenza Rimassa, Mar Lozano, Jesús M. González Santiago, Frank Tacke, Margarita Sala, María Anders, Anja Lachenmayer, Federico Piñero, Alex França, Maria Guarino, Alessandra Elvevi, Giuseppe Cabibbo, Markus Peck-Radosavljevic, Ángela Rojas, Mercedes Vergara, Chiara Braconi, Sonia Pascual, Christie Perelló, Vivianne Mello, Carlos Rodríguez-Lope, Juan Acevedo, Rosanna Villani, Clemence Hollande, Valérie Vilgrain, Ahmed Tawheed, Carmem Ferguson Theodoro, Zeno Sparchez, Lorraine Blaise, Daniele E. Viera-Alves, Robyn Watson, Flair J. Carrilho, Carlos Moctezuma-Velázquez, Antonio D'Alessio, Massimo Iavarone, Maria Reig

Subjects
Settore MED/12 - Gastroenterologia, Carcinoma, Hepatocellular, Hepatology, Hepatocellular carcinoma, SARS-CoV-2, Liver Neoplasms, COVID-19, hepatocellular carcinoma, mortality, Cohort Studies, liver cancer, COVID-19 Testing, Cross-Sectional Studies, Humans, Mortality, Liver cancer, Retrospective Studies
Abstract

Background & Aims Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Results Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84–11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24–12.74], 11.76% [95% CI 4.73–22.30], 20.69% [95% CI 11.35–31.96] and 34.52% [95% CI 17.03–52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49–4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29–7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. Conclusions This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period., Spanish Health Ministry; Ricerca Corrente, Grant/Award Number: RC2019/105-01, RC2018/105-01 and RC2017/105-01; European Association for the Study of the Liver (Andrew Burroughs Fellowship); Cancer Treatment and Research Trust (CTRT); Wellcome Trust Strategic Fund, Grant/Award Number: PS3416; Cancer Research UK (CR UK) centre, Grant/Award Number: C9380/A26813, C18342/A23390 and C9380/A18084; Instituto de Salud Carlos III, Grant/Award Number: PI18/0358, PI15/00145, CD18/00126, PI19/00819, FI19/00222, 16-0026, PI044031, PI18/00768, PI18/00542 and PI13/01229; Bristol Myers Squibb and Celgene; Cancer Research UK, Grant/Award Number: RCCPDB-Nov21/100008

Published
2022

231. Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection.

Author

Pelizzaro, Filippo, Trevisani, Franco, Simeon, Vittorio, Vitale, Alessandro, Cillo, Umberto, Piscaglia, Fabio, Missale, Gabriele, Sangiovanni, Angelo, Foschi, Francesco G., Cabibbo, Giuseppe, Caturelli, Eugenio, Di Marco, Maria, Azzaroli, Francesco, Brunetto, Maurizia R., Raimondo, Giovanni, Vidili, Gianpaolo, Guarino, Maria, Gasbarrini, Antonio, Campani, Claudia, and Svegliati‐Baroni, Gianluca

Subjects
LIVER cancer, LIVER, OVERALL survival, DISEASE relapse, DATABASES
Abstract

Background and Aims: Hepatocellular carcinoma (HCC) recurrence is common in patients treated with liver resection (LR). In this study, we aimed to evaluate the incidence and preoperative predictors of non‐transplantable recurrence in patients with single HCC ≤5 cm treated with frontline LR. Methods: From the Italian Liver Cancer (ITA.LI.CA) database, 512 patients receiving frontline LR for single HCC ≤5 cm were retrieved. Incidence and predictors of recurrence beyond Milan criteria (MC) and up‐to‐seven criteria were compared between patients with HCC <4 and ≥4 cm. Results: During a median follow‐up of 4.2 years, the overall recurrence rate was 55.9%. In the ≥4 cm group, a significantly higher proportion of patients recurred beyond MC at first recurrence (28.9% vs. 14.1%; p < 0.001) and overall (44.4% vs. 25.2%; p < 0.001). Similar results were found considering recurrence beyond up‐to‐seven criteria. Compared to those with larger tumours, patients with HCC <4 cm had a longer recurrence‐free survival and overall survival. HCC size ≥4 cm and high alpha‐fetoprotein (AFP) level at the time of LR were independent predictors of recurrence beyond MC (and up‐to‐seven criteria). In the subgroup of patients with available histologic information (n = 354), microvascular invasion and microsatellite lesions were identified as additional independent risk factors for non‐transplantable recurrence. Conclusions: Despite the high recurrence rate, LR for single HCC ≤5 cm offers excellent long‐term survival. Non‐transplantable recurrence is predicted by HCC size and AFP levels, among pre‐operatively available variables. High‐risk patients could be considered for frontline LT or listed for transplantation even before recurrence. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

235. Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: Who is the winner?

Author

Celsa, C., primary, Cabibbo, G., additional, Rizzo, G.E.M., additional, Giuffrida, P., additional, Enea, M., additional, Di Maria, G., additional, Antonucci, M., additional, Giacchetto, C.M., additional, Rancatore, G., additional, Grassini, M.V., additional, Ciccia, R., additional, Grova, A., additional, Salvato, M., additional, Battaglia, S., additional, Vaccaro, M., additional, and Cammà, C., additional

Published
2023
Full Text
View/download PDF

236. Preoperative predictors of recurrence beyond Milan criteria in hepatocellular carcinoma patients treated with frontline liver resection

Author

Pelizzaro, F., primary, Trevisani, F., additional, Vitale, A., additional, Cillo, U., additional, Piscaglia, F., additional, Missale, G., additional, Sangiovanni, A., additional, Foschi, F.G., additional, Cabibbo, G., additional, Caturelli, E., additional, Di Marco, M., additional, Azzaroli, F., additional, Brunetto, M.R., additional, Raimondo, G., additional, Vidili, G., additional, Guarino, M., additional, Gasbarrini, A., additional, Campani, C., additional, Svegliati-Baroni, G., additional, Giannini, E.G., additional, Mega, A., additional, Masotto, A., additional, Rapaccini, G.L., additional, Magalotti, D., additional, Sacco, R., additional, Nardone, G., additional, and Farinati, F., additional

Published
2023
Full Text
View/download PDF

237. OC.08.2 NETWORK META-ANALYSIS OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: WHO IS THE WINNER?

Author

Celsa, C., primary, Cabibbo, G., additional, Rizzo, G.E.M., additional, Giuffrida, P., additional, Di Maria, G., additional, Battaglia, S., additional, Vaccaro, M., additional, Enea, M., additional, Giacchetto, C., additional, Rancatore, G., additional, Grassini, M., additional, Ciccia, R., additional, Grova, A., additional, Salvato, M., additional, and Camma, C., additional

Published
2023
Full Text
View/download PDF

238. OC.12.4 PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH LENVATINIB

Author

Sacco, R., primary, Ciruolo, M., additional, Paolillo, R., additional, Ramai, D., additional, Tortora, R., additional, Di, Costanzo G.G., additional, Burlone, M., additional, Pirisi, M., additional, Federico, P., additional, Daniele, B., additional, Silletta, M., additional, Gallo, P., additional, Cocuzza, C., additional, Russello, M., additional, Cabibbo, G., additional, Cesario, S., additional, Masi, G., additional, Marzi, L., additional, Mega, A., additional, Granito, A., additional, Pieri, G., additional, Giannini, E., additional, Gadaleta-Caldarola, G., additional, Dadduzio, V., additional, Giordano, G., additional, Giacomelli, L., additional, Papa, S., additional, Renzulli, M., additional, Maida, M., additional, Ghidini, M., additional, and Facciorusso, A., additional

Published
2023
Full Text
View/download PDF

240. Heart rate variability is associated with disease severity and portal hypertension in cirrhosis

Author

Miceli, Giuseppe, primary, Calvaruso, Vincenza, additional, Casuccio, Alessandra, additional, Pennisi, Grazia, additional, Licata, Massimo, additional, Pintus, Chiara, additional, Basso, Maria G., additional, Velardo, Mariachiara, additional, Daidone, Mario, additional, Amodio, Emanuele, additional, Petta, Salvatore, additional, Simone, Fabio, additional, Cabibbo, Giuseppe, additional, Di Raimondo, Domenico, additional, Craxì, Antonio, additional, Pinto, Antonio, additional, and Tuttolomondo, Antonino, additional

Published
2023
Full Text
View/download PDF

241. Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis

Author

Sacco, Rodolfo, primary, Ramai, Daryl, additional, Tortora, Raffaella, additional, di Costanzo, Giovan Giuseppe, additional, Burlone, Michela Emma, additional, Pirisi, Mario, additional, Federico, Piera, additional, Daniele, Bruno, additional, Silletta, Marianna, additional, Gallo, Paolo, additional, Cocuzza, Caterina, additional, Russello, Maurizio, additional, Cabibbo, Giuseppe, additional, Rancatore, Gabriele, additional, Cesario, Silvia, additional, Masi, Gianluca, additional, Marzi, Luca, additional, Mega, Andrea, additional, Granito, Alessandro, additional, Pieri, Giulia, additional, Giannini, Edoardo G., additional, Paolillo, Rosa, additional, Gadaleta-Caldarola, Gennaro, additional, Dadduzio, Vincenzo, additional, Giordano, Guido, additional, Giacomelli, Luca, additional, Papa, Simonetta, additional, Renzulli, Matteo, additional, Maida, Marcello, additional, Ghidini, Michele, additional, Borzio, Mauro, additional, and Facciorusso, Antonio, additional

Published
2023
Full Text
View/download PDF

246. Transarterial radioembolization for hepatocellular carcinoma: a review

Author

Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, Eggenhoffner R, Bresci G, Cabibbo G, and Giacomelli L

Subjects
hepatocellular carcinoma, transarterial radioembolization, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Rodolfo Sacco,1 Caterina Conte,2 Emanuele Tumino,1 Giuseppe Parisi,1 Sara Marceglia,3 Salvatore Metrangolo,1 Roberto Eggenhoffner,4 Giampaolo Bresci,1 Giuseppe Cabibbo,5 Luca Giacomelli4 1Department of Gastroenterology, Cisanello Hospital, Pisa, 2Endocrinology and Metabolic Diseases, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome, 3Department of Engineering and Architecture, University of Trieste, Trieste, 4Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, Genova University, Genoa, 5Section of Gastroenterology, DIBIMIS, University of Palermo, Palermo, Italy Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. The treatment of HCC is complex and includes potentially curative and palliative approaches. However, both curative and palliative treatments for HCC are often associated with a not-completely favorable safety/efficacy ratio. Therefore, other treatment options appear necessary in clinical practice. Transarterial radioembolization has shown a promising efficacy in terms of disease control and is associated with a good safety profile. This review discusses the use of transarterial radioembolization in HCC, with a focus on the clinical aspects of this therapeutic strategy. Keywords: hepatocellular carcinoma, transarterial radioembolization

Published
2016

248. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study

Author

Vitale, Alessandro, Burra, Patrizia, Frigo, Anna Chiara, Trevisani, Franco, Farinati, Fabio, Spolverato, Gaya, Volk, Michael, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Gasbarrini, Antonio, Sacco, Rodolfo, Foschi, Francesco Giuseppe, Missale, Gabriele, Morisco, Filomena, Svegliati Baroni, Gianluca, Virdone, Roberto, and Cillo, Umberto

Published
2015
Full Text
View/download PDF

250. Microstructure and Mechanical Properties of Spark Plasma Sintered CoCrFeNiNbX High-Entropy Alloys with Si Addition

Author

Miroslav Karlík, Filip Průša, Petr Kratochvíl, Hana Thürlová, Angelina Strakošová, Jaroslav Čech, Jiří Čapek, Marek Vronka, Marcello Cabibbo, and Ondřej Ekrt

Subjects
General Materials Science, high-entropy alloys, mechanical alloying, spark plasma sintering, X-ray diffraction, electron microscopy, instrumented indentation, compression testing
Abstract

Three mechanically alloyed (MA) and spark plasma sintered (SPS) CoCrFeNiNbX (X = 5, 20, and 35 at.%) alloys with an addition of 5 at.% of SiC were investigated. The face-centered cubic (FCC) high-entropy solid solution, NbC carbides, and hexagonal Laves phase already developed during MA. In addition, the SPS compacting led to the formation of oxide particles in all alloys, and the Cr7C3 carbides in the Nb5 alloy. The fraction of the FCC solid solution decreased with increasing Nb concentration at the expense of the NbC carbide and the Laves phase. Long-term annealing at 800 °C led to the disappearance of the Cr7C3 carbide in the Nb5 alloy, and new oxides—Ni6Nb6O, Cr2O3, and CrNbO4—were formed. At laboratory temperature, the Nb5 alloy, containing only the FCC matrix and carbide particles, was relatively strong and very ductile. At a higher Nb content (Nb20 and Nb35), the alloys became brittle. After annealing for 100 h at 800 °C, the Nb5 alloy conserved its plasticity and the Nb20 and Nb35 alloys maintained or even increased their brittleness. When tested at 800 °C, the Nb5 and Nb20 alloys deformed almost identically (CYS ~450 MPa, UTS ~500 MPa, plasticity ~18%), whereas the Nb35 alloy was much stronger (CYS of 1695 MPa, UCS of 1817 MPa) and preserved comparable plasticity.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results